Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical progr

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess

US stocks rise, Nasdaq up 150 points. Dow up 0.13%, Nasdaq up 0.62%, S&P 500 up 0.35%. IT shares

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p

CRWV shares rose in pre-market trading after reporting better-than-expected Q2 results. BAOS, BOXL,

GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Comp

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-

Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expect

US stocks mixed, Nasdaq up 0.39% as Dow down 0.03%. Target Corp beats earnings, oil down 2.4% and mo

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204

Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(0.85) per share which beat the an

Dow Jones falls 500 points, S&P drops 1.29%, NASDAQ down 1.79%. Energy shares rise 1.2%, tech st

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-

Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clin

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clin

The CTA was submitted through the EU Clinical Trials Information System (CTIS), with Germany serving

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic c

Silexion Therapeutics Corp (NASDAQ: SLXN - Get Free Report) was down 0.9% during mid-day trading on

Significant regulatory milestone marks advancement into clinical-stage development of next-generatio

Significant regulatory milestone marks advancement into clinical-stage development of next-generatio

Significant regulatory milestone marks advancement into clinical-stage development of next-generatio

Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(1.40) per share which missed the

Throughout the year, the Company reported significant positive preclinical findings for SIL204 acros